Accueil
Envoyer à un ami
Imprimer
Grand
Petit
Partager
ACTUALITES

Boehringer Ingelheim launches ambitious ELUXA trial programme to broadly investigate promising ...


- 2 Juin 2016 modifié le 1 Janvier 1970


  • Comprehensive ELUXA trial programme explores olmutinib* (BI 1482694) as a monotherapy and in several combination studies
  • Olmutinib will be studied in combination with the immuno-oncology therapy Keytruda®+, second-generation TKI Giotrif®/Gilotrif®**, anti-angiogenic agents Vargatef®*** and Avastin®, and Boehringer Ingelheim's investigational IGF mAb BI 836845****
  • Accelerated trial programme underway with ELUXA 1 trial fully enrolled; additional Phase III trials to start soon


ACTUALITES | INTERNATIONAL | TCHAD | POLITIQUE | CULTURE | EXCLUSIF | Revue de Presse | English News | 中國